We maintain several equity incentive plans under which we may grant incentive stock options, nonqualified stock options, stock bonuses, restricted stock awards, restricted stock units and stock appreciation rights to employees (including officers), non-employee directors and consultants.

We account for stock-based compensation by recording the estimated fair value of stock-based awards granted as compensation expense over the vesting period, net of estimated forfeitures. Stock-based compensation expense is attributed to earnings using a straight-line method. We estimate forfeitures of stock-based awards based on historical experience and expected future activity.

The fair value of restricted stock awards and units is measured based on the closing price of our common stock on the date of grant. The fair value of stock option grants is estimated on the date of grant using the Black-Scholes option pricing model.

Total stock-based compensation expense is recognized on our condensed consolidated statements of operations as follows (in thousands):

	Three Months Ended
	May 1, 2021		May 2, 2020
Cost of goods sold	$	371	$	319
Selling, general and administrative expenses		1,369		1,237
Total stock-based compensation expense	$	1,740	$	1,556

At May 1, 2021, there was $12.7 million of total unrecognized compensation cost related to unvested stock options, restricted stock awards and restricted stock units. This cost has a weighted-average remaining recognition period of 1.4 years.

The following table summarizes restricted stock awards and restricted stock units activity (in thousands, except grant date weighted-average fair value):

	Restricted Stock Awards/Units			Grant Date Weighted- Average Fair Value		Intrinsic Value
Outstanding at January 30, 2021		600		$	21.41
Granted		127		$	45.29
Vested		(207	)	$	20.97
Forfeited		(18	)	$	21.62
Outstanding at May 1, 2021		502		$	27.64	$	21,561

We had 0.3 million stock options outstanding at May 1, 2021 with a weighted average exercise price of $26.10 and 0.3 million stock options outstanding at January 30, 2021 with a weighted average exercise price of $22.08.